Abstract: Intrahepatic cholangiocarcinoma is the second most common subtype of primary hepatobilliary cancer. Despite advances in surgical and medical therapy, its survival rate remains poor. Compared to hepatocellular carcinoma (HCC), the most common liver malignancy, the underlying mechanisms of cholangiocarcinoma carcinogenesis are poorly characterized. P-cadherin (CDH3) is a cadherin super family member. Although CDH3 is frequently over-expressed in cholangiocarcinoma tissues, its roles have never been characterized. To determine the roles of CDH3 in cholangiocarcinoma, we investigated CDH3 function in HuCCT1 cells using specifi c siRNA. Transfection with CDH3 siRNA did not aff ect proliferation of HuCCT1 cells. However, cell migration and invasion were signifi cantly reduced when CDH3 was down-regulated. In addition, expressions of several biomarkers for epithelial-mesenchymal transition (EMT) were not changed by CDH3 down-regulation. Th ese results suggest that CDH3 regulates cell migration independent of EMT in cholangiocarcinoma cells.
Introduction
Cholangiocarcinoma is a malignant tumor originated from bile duct epithelial cells (Olnes & Erlich, 2004) . Intrahepatic cholangiocarcinoma is the second most common subtype of primary hepatobilliary cancer (Kato et al., 1990; TaylorRobinson et al., 1997; Olnes & Erlich, 2004; Shaib et al., 2004) . Between 1973 and 1997, the incidence and mortality rates of intraheptic cholangiocarcinoma in the United States was increased by approximately 9%, and is the most common primary liver cancer-related cause of death in the United Kingdom. The mortality rate of intrahepatic cholangiocarcinoma has increased in Japan, Western Europe, and Australia between 1979 and 1998. There is significant program. To detach from the primary tumor and invade into the surrounding tissue, tumor cells have to break down cellcell contacts and the remodel cell-matrix adhesion sites. Th ese processes are known as epithelial-mesenchymal transition (EMT). During EMT, non-motile and polarized epithelial cells that are usually embedded via cell-cell junctions in a cell collective, dissolve their cell-cell junctions and convert into individual, non-polarized, motile and invasive mesenchymal cells (Yilmaz & Christofori, 2009) .
Many EMT biomarkers have been reported (Zeisberg & Neilson, 2009) . One of most important biomarkers is downregulation of E-cadherin. E-cadherin is a cell-cell adhesion molecule expressed on the membrane of epithelial cells. Moreover, cancer cells undergoing EMT gain mesenchymal markers, including N-cadherin, P-cadherin, vimentin, collagen 1 and 2. EMT can be prompted by various intrinsic signals (e.g. gene mutations) as well as extrinsic signals (e.g. growth factor signaling) (Yilmaz & Christofori, 2009 ). Among the growth factors known to induce EMT are transforming growth factor β (TGFβ), hepatocyte growth factor (HGF), members of the epidermal growth factor (EGF) family, insulin-like growth factor (IGF) and fi broblast growth factor (FGF).
Cadherins (Calcium dependent adhesion molecules) are transmembrane proteins which play a role in cell to cell adhesion and junction (Takeichi 1995) . The majority of studies on cadherins have focused on E-cadherin (CDH1) and N-cadherin (CDH2). E-cadherin is the prototype family member of classical cadherins, single-span transmembrane glycoproteins that interact in a calcium-dependent, hemophilic manner with E-cadherins on neighboring cells. E-cadherin-mediated cell-cell adhesion complexes are anchored to the actin cytoskeleton via its cytoplasmic domain, β-catenin and α-catenin. N-cadherin also forms hemophilic cell-cell adhesion junctions. It is normally expressed in nervous tissue, vascular endothelial cells and in skeletal and cardiac muscle cells. It is found to be localized in the lamellipodia and fi llopodia. P-cadherin (CDH3) is one of the cadherin super family members and fi rst identifi ed in mouse placenta (Nose & Takeichi, 1986) . In human its expression is not detectable in the placenta but is present in a few organs, such as mammary gland and prostate (Taniuchi et al., 2005) . Unlike the E-and N-cadherins, CDH3 has not fully been investigated and its roles remain unclear. Although previous studies have shown that CDH3 was related to various cancers, such as breast cancer (Paredes et al., 2005; Paredes et al., 2008; Gorski et al., 2009) , colorectal cancer (Milicic et al., 2008; Hibi et al., 2009a) , gastric cancer (Hibi et al., 2009b) , head and neck cancer (Dasgupta et al., 2006) , ovarian cancer (Cheung et al., 2010) , and pancreatic cancer (Taniuchi et al., 2005; Imai et al., 2008) , the pathological roles played by CDH3 remain poorly investigated.
Compared to HCC, the underlying mechanisms of cholangiocarcinoma carcinogenesis are poorly characterized. A previous study showed that CDH3 is frequently overexpressed in cholangiocarcinoma cells (Obama et al., 2005) . However its roles in cholangiocarcinoma cells have not yet been characterized. Th e aim of this study was to demonstrate the roles CDH3 play in cholangiocarcinoma cells.
Materials and Methods

Cell culture and transfection
HuCCT1 cell line was purchased from the Health Science Research Resources Bank (Osaka, Japan). HuCCT1 cells were cultured with RPMI1640, 10% FBS and 1x penicillin/ streptomycin at 37 o C and 5% CO 2 incubator. CDH3 siRNA (Bioneer, Daejeon, Korea) and scrambled (SCR) siRNA (Dhamacon, Lafayette, CO, USA) were purchased. Cells were transfected with 100 nM of CDH3 siRNA, or SCR siRNA with Dhamafect reagent (Dhamacon, Lafayette, CO, USA) in accordance with the manufacturer's protocol. SCR siRNA was used as negative control. Th e sequences of CDH3 siRNA duplex were as follows: 5'-CUC UCU GGA AUG GAA CCU U-3', 5'-GAC UGA CCU ACA GUG GAC U-3', and 5'-GUG ACA ACG UCU UCU ACU A-3'
Proliferation assay
Four days aft er transfection of CDH3 siRNA into HuCCT1 cells in a 96-well plate, 10 ul of Ez-Cytox (ITSBIO, Seoul, Korea) were added and incubated for 2 h under normal cell culture conditions. Cell viability was measured by absorbance at 450 nm using an ELISA reader (TECAN, Mannedorf, Switzerland).
Wound-healing assay
A day after transfection of CDH3 siRNA into HuCCT1 cells in a 6-well plate, cells were transferred and cultured to a 48-well plate until confl uent. Th ree hours following treatment with mitomycin C at 5 μg/ml (Sigma-Aldrich, St. Louis, MO, USA), cells were scratched using 200 ul yellow tips and 
Matrigel invasion assay
As described by Jeon et al. (Jeon et al., 2010) , following a day of transfection with SCR or CDH3 siRNA into HuCCT1 cells, transfected cells were seeded to a 24-well BioCoat TM Matrigel TM chamber inserts (BD Biosciences, San Jose, CA, USA). After 36 h, cells on the inside of the inserts were removed with cotton tips, and the invaded cells on the outside of the inserts were visualized using hematoxylin/eosin staining.
Real-time RT-PCR
Total RNA was extracted using RNeasy Mini kit (Qiagen, Valencia, CA, USA) in accordance with the manufacturer's protocol. cDNA was synthesized with MMLV reverse transcriptase (Promega, Madison, WI, USA), dNTP and oligodT primers. Real-time RT-PCR was carried out using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster city, CA, USA) in the ABI Prism 7500 sequence detector (Applied Biosystems, Foster city, CA, USA) in accordance with the manufacturer's protocol. Th e primer sequences were as follows: CDH1 (F: 5'-TGG GCC AGG AAA TCA CAT CC-3', R: 5'-CTC AGC CCG AGT GGA AAT GG-3'), CDH3 (F: 5'-CCC CCA GAA GTA CGA GGC CCA-3', R: 5'-ACG CCA CGC TGG TGA GTT GG-3'), Fibronectin (F: 5'-GAG CTG CAC ATG TCT TGG GAA C-3', R: 5'-GGA GCA AAT GGC ACC GAG ATA-3'), SNAI1 (F: 5'-GGA CCC ACA CTG GCG AGA AG-3', R: 5'-ATT CGG GAG AAG GTC CGA GC-3'), SNAI2 (F: 5'-TTG CAA GAT CTG CGG CAA GG-3', R: 5'-AAT GCT CTG TTG CAG TGA GGG C-3'), Vimentin (F: 5'-TGA GTA CCG GAG ACA GGT GCA G-3', R: 5'-TAG CAG CTT CAA CGG CAA AGT TC-3') and β-actin (F: 5'-CAA GAG ATG GCC ACG GCT GC-3', R: 5'-TCC TTC TGC ATC CTG TCG GC-3'). β-actin was used as a loading control and all signals were normalized to β-actin.
Western blotting
Transfected cell lysates were run onto 10% SDS-PAGE gel and transferred to a PVDF membrane. Blocking was carried out with 3% BSA in PBS for 1 h at room temperature. CDH3 antibody (BD Biosciences, CA, USA) was diluted to 1 : 500 in 3% BSA in PBS, and incubated overnight at 4 o C. 
Data analysis
All data are presented as means±SEM. All experiments were repeated at least 4 times. The difference between the mean values of two groups was evaluated using the Student's t-test (unpaired comparison). For comparison of more than three groups, we used one-way analysis of variance (ANOVA) test followed by Tukey's multiple comparison. A P value of <0.05 was considered statistically signifi cant.
Results
CDH3 is knockdowned through the siRNA
Prior to investigating CDH3 functions in cholangiocarcinoma cells using siRNA, we checked whether CDH3 siRNA specifically down-regulate its expression level. Cells were harvested two days after transfection with CDH3 or scrambled siRNA. Real-time RT-PCR showed transfection of CDH3 siRNA into HuCCT1 cells dramatically decreased its mRNA expression level while scrambled control siRNA made no impact (Fig. 1A) . CDH3 protein level was measured by Western blotting using CDH3 antibody. CDH3 siRNA significantly reduced its protein level, whereas scrambled siRNA did not (Fig. 1B) . These results indicate that CDH3 siRNA could specifically down-regulate CDH3 expression level in HuCCT1 cells.
CDH3 has no eff ect on cell proliferation
Previous reports showed that CDH3 promoter is hypomethylated and highly expressed in various cancer cells and tissues (Milicic et al., 2008; Hibi et al., 2009a; Hibi et al., 2009b) . However, the roles of CDH3 in cell proliferation are poorly characterized, especially in cholangiocarcinoma cells. We therefore carried out cell proliferation assay to determine whether CDH3 affects cell proliferation in cholangiocarcinoma cells. Different concentration series of CDH3 siRNA were transfected into HuCCT1 cells 1 d after cell seeding. Following 4 d of siRNA transfection, cell proliferation assay was performed as described in the Materials and Methods section. As shown in Fig. 2 , downregulation of CDH3 did not aff ect cell proliferation, consistent with a previous report (Cheung et al., 2010) . Th is data suggest that CDH3 plays in other cellular events rather than cell proliferation in cholangiocarcinoma cells.
Cell migration is decreased by CDH3 knockdown
Previous reports showed that CDH3 aff ects cell migration in pancreatic cancer cells (Taniuchi et al., 2005) and ovarian cancer cells (Cheung et al., 2010) . We hypothesize that CDH3 regulates cell migration in cholangiocarcinoma cells. In order to verify this hypothesis, CDH3 siRNA or scrambled siRNA was transfected into HuCCT1 cells, and cell migration was examined using wound-healing assay. Fig. 3 shows that downregulation of CDH3 decreased cell migration rate in HuCCT1, compared to control and scrambled siRNA. To confi rm this data, we conducted matrigel invasion assay, which is a gold standard cancer cell migration and invasion assay. As shown in Fig. 4 , invasion of HuCCT1 cells through the matrigel was signifi cantly reduced when CDH3 was knock-downed. Th ese results are consistent with previous reports (Taniuchi et al., 2005; Cheung et al., 2010) , and suggest that CDH3 positively aff ect cell migration in HuCCT1 cells.
CDH3 is not related with EMT
To reveal how CDH3 regulates cell migration in HuCCT1 cells, we decided to study EMT because it can affect cancer cell migration and invasion (Yilmaz & Christofori, 2009 ). To determine whether EMT is involved in the eff ects of CDH3 on cell migration, change in expression level of EMT-related genes was measured, using real time RT-PCR after CDH3 knock-down. Fig. 5 shows that the mRNA expression levels of mesenchymal markers (snail1, snail2, and vimentin) were not signifi cantly changed. Although the expression level of CDH1 was increased, there was no change in CDH2 expression level during CDH3 knockdown (data not shown). Th is result implies that CDH3-dependent cell migration may not involve EMT. 
Discussion
The carcinogenesis of cholangiocarcinoma has been poorly characterized compared to HCC. Over-expression of CDH3 in patients with cholangiocarcinoma has been shown in a previous report (Obama et al., 2005) . However, its roles in carcinogenesis of cholangiocarcinoma have never been examined. In the present study, we show that CDH3 regulates migration rather than proliferation in cholangiocarcinoma.
Metastatic cancers can preclude curative surgical resection and results in poor prognosis. Over-expression of CDH3 was reported to be associated with aggressive character and poor prognosis in breast and endometrial cancers (Peralta Soler et al., 1999; Gamallo et al., 2001; Stefansson et al., 2004) . Although over-expression of CDH3 in cholangiocarcinoma tissues was reported in an immunohistochemistry study (Obama et al., 2005) , associations between its expression and lymph node metastasis, distant metastasis or gross appearance were not observed. It must be emphasized that only 23 tumors specimens from patients were analyzed. Further studies including more tissues specimens should be conducted.
Th ere are controversies surrounding the roles of CDH3 in cancer cells migration. CDH3 is known to promote migration in pancreatic and ovarian cancer (Taniuchi et al., 2005; Cheung et al., 2010) . In contrast, in mammary epithelial cells, CDH3 inhibited migration (Simpson et al., 2008) . When Panc-1 cells were stably transfected with full-length CDH3 cDNA, cell migration was significantly enhanced although N-cadherin expression was significantly reduced (Taniuchi et al., 2005) . In CDH3-overexpressing Panc-1 cells, the activities of Rac1 and Cdc42 were significantly increased (Taniuchi et al., 2005) . Moreover, when OVCAR-3 cells and Caov-3 cells were stably transfected with CDH3 cDNA, cell migration and invasion were significantly enhanced (Cheung et al., 2010) . When CDH3 expression was downregulated using CDH3 siRNA in these cells, cell migration and invasion was significantly reduced. In contrast to these results, when CDH3 expression was down-regulated using CDH3 siRNA in MCF-10A cells (mammary epithelial cells), cell migration was significantly enhanced (Simpson et al., 2008) . Th is discrepancy may be due to diff erent roles CDH3 play, depending on cell type. Another explanation may be that MCF-10A cells are non-cancerous cells, whereas Panc-1, Caov-3, and OVCAR-3 cells are cancerous cells. As such, the roles of CDH3 in cancerous cells and non-cancerous cells may be diff erent. In the present study, CDH3 siRNA inhibited migration of cholangiocarcinoma cells in two experiments: wound healing assay, and matrigel invasion assay. Th e results suggest that CDH3 in cancerous cells supports cell migration.
Previous reports suggested possible mechanisms on how CDH3 regulates migration of cancer cells. Taniuchi et al. showed that p120-catenin was involved in the regulation of motility by CDH3 (Taniuchi et al., 2005) . P120-catenin is found in two forms, one bound to cadherins under the plasma membrane and the other in the cytoplasm (Kinch et al., 1995; Staddon et al., 1995; Anastasiadis & Reynolds, 2001) . Different types of cadherins regulate cell movement by controlling the levels of p120-catenin present in the cytoplasmic pool. Taniuchi et al. showed that cytoplasmic accumulation of p120-catenin significantly correlated with CDH3 levels but not with the levels of E-cadherin or N-cadherin (Taniuchi et al., 2005) . Diff erent distribution may be due to diff erent affi nity of p120 for each classic cadherin. Because of the low affi nity for CDH3, more p120-catenin is distributed in the cytoplasm when CDH1 is replaced with CDH3 by EMT. In addition, Taniuchi et al. showed that activation of Rac1 and Cdc42 by CDH3 was inhibited by p120-catenin siRNA, which suggested that p120-catenin activated Rac1 and Cdc42 GTPases, which are known modulators of actin dynamics essential for cell migration and invasion (Yilmaz & Christofori, 2009) .
Another mechanism on how p120-catenin regulates cell migration and invasion may involve transcriptional repressor Kaiso (van Roy & McCrea, 2005) . P120-catenin can transfer to the nucleus where it binds to Kaiso. In contrast to β-catenin/Tcf-mediated transcriptions, where β-catenin acts as transactivator, p120-catenin has no transactivation domain, but rather release Kasio from its promoter binding sites, thereby activates gene expression by de-repression. However, the nature of p120/Kaiso target genes is still poorly defined (Yilmaz & Christofori, 2009) .
Cadherins have been shown to play roles in signal transduction in addition to their structural roles in adhesion and migration (Pece & Gutkind, 2000; Suyama et al., 2002; Qian et al., 2004) . For example, E-cadherin is associated with epidermal growth factor receptor (EGFR), thus activating the mitogen-activated protein kinase pathway. N-cadherin has also been found to interact with fibroblast growth factor receptor (FGFr). Moreover, interaction between CDH3 and insulin-like growth factor receptor (IGFRr) has been suggested. Furthermore, EMT is regulated by various growth factors, including EGF, FGF, HGF and IGF, whose signaling is fi nally transmitted into the nucleus where the key transcription factors, such as SNAI1, SNAI2, ZEB1 and ZEB2 are induced (Th iery et al., 2009; Yilmaz & Christofori, 2009) . Th ese results suggest that a change in CDH3 expression level may modulate EMT induced by a certain growth factor. To test this hypothesis, we examined change in the expression of EMT marker genes following transfection with CDH3 siRNA. However, we did not observe consistent changes in EMT marker genes expression (Fig. 5) .
Although other EMT marker genes including SNAI1, SNAI2, and vimentin were not significantly changed after transfection with CDH3 siRNA, the expression of CDH1 was increased, which may suggest redundancy in the level of cadherins (Fig. 5) . During EMT in carcinogenesis, cadherin switch has been well documented (Zeisberg & Neilson, 2009 ). However, effects of change in the expression of CDH3 on other cadherins expression were different in different cells. Th e expression level of CDH1 or CDH2 was not changed by over-expression or knock-down of CDH3 in ovarian cancer cells (Cheung et al., 2010) . Th e expression level of CDH2 was reduced however that of CDH1 was not changed by overexpression of CDH3 in pancreatic cancer cells (Taniuchi et al., 2005) .
The roles of cadherins in signal transduction pathway indicate that they can regulate proliferation. N-cadherin negatively controls osteoblast proliferation and survival via inhibition of autocrine/paracrine Wnt3a ligand expression and attenuation of Wnt, ERK and PI3K/Akt signaling (Haÿ et al., 2009 ). E-cadherin can negatively regulate, in an adhesiondependent manner, ligand-dependent activation of divergent classes of receptor tyrosine kinases (RTKs), by inhibiting their ligand-dependent activation in association with decreases in receptor mobility and in ligand-binding affinity (Qian et al., 2004) . As such, E-cadherin neutralizing antibody inhibited proliferation of MDCK cells. However, according to published reports, CDH3 does not regulate cell proliferation, although CDH3 is highly expressed in numerous cancer tissues (Taniuchi et al., 2005; Milicic et al., 2008; Cheung et al., 2010) . In Panc-1 cells, neither over-expression of CDH3 nor functional-blocking of CDH3 regulated cell proliferation (Taniuchi et al., 2005) . Moreover, when OVCAR-3 cells and Caov-3 cells were stably transfected with CDH3 cDNA, cell proliferation was not affected (Cheung et al., 2010) . Furthermore, the crypt fission rate was not significantly increased in CDH3 transgenic mouse that harbored CDH3 over-expression in the intestinal and colonic epithelium (Milicic et al., 2008) . Consistent with these results, the present study showed that down-regulation of CDH3 did not affect proliferation in cholangiocarcinoma cells.
In summary, CDH3 regulates cell migration through EMTindependent signaling in cholangiocarcinoma cells. Our data will contribute to the development of diagnostic molecular markers and therapies against cholangiocarcinoma.
